Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver

BMC Gastroenterology

Peter Malfertheiner¹  Jens Ricke²  Jörg Arend⁴  Tina Bretschneider²  Jan Bornschein¹  Kai Antweiler³  Janine Poranzke¹  Christian Schulz¹  Kerstin Schütte¹ 

[1] Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, Magdeburg 39120, Germany;Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany;Institute for Biometry and Medical Informatics, Otto-von-Guericke University, Magdeburg, Germany;Department of General, Visceral and Vascular Surgery, Otto-von-Guericke University, Magdeburg, Germany

关键词: NAFLD;    Non-cirrhotic liver;    Liver cirrhosis;    Prognosis;    Hepatocellular carcinoma;   

Others  :  854671
DOI  :  10.1186/1471-230X-14-117

 received in 2014-02-23, accepted in 2014-06-26,  发布年份 2014

【 摘 要 】

Background

HCC predominantly develops in the condition of chronic inflammation that has led to liver cirrhosis. A small proportion of patients with HCC is diagnosed in the non-cirrhotic liver (NCL). Data on patients with HCC in NCL in advanced stages are scarce.

Methods

A retrospective analysis was performed comparing 93 patients with HCC in NCL to 571 patients with HCC in liver cirrhosis (LC) with respect to clinical and demographic characteristics. Also factors influencing survival in patients with HCC in NCL were analyzed.

Results

Patients with HCC in NCL were diagnosed at older age and in more advanced tumor stages than patients with LC. More than 25% of patients with HCC in NCL presented with extrahepatic metastases. Only a minority of patients with HCC in NCL lacked any sign of hepatic damage. Risk factors for LC and risk factors for NAFLD are present in the majority of patients with HCC in NCL. The BCLC classification corresponded with the survival of patients with HCC in NCL although the therapeutic options differ from those for patients with liver cirrhosis.

Conclusions

It will be one of the major challenges in the future to awake awareness of carrying a risk of hepatic malignancies in patients with chronic liver diseases apart from liver cirrhosis, especially in NAFLD. Surveillance programs need to be implemented if these are cost-effective.

【 授权许可】

   
2014 Schütte et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011, 365(12):1118-1127.
• [2]Schütte K, Bornschein J, Malfertheiner P: Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis 2009, 27(2):80-92.
• [3]Globocan 2008. http://globocan.iarc.fr/ webcite
• [4]Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M: Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010, 42(5):341-347.
• [5]Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, Hansen T, Pitton MB, Niederle IM, Schuchmann M, Weinmann A, Düber C, Galle PR, Otto G: Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol 2012, 47(6):718-728.
• [6]Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J, Malfertheiner P: Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion 2013, 87(3):147-159.
• [7]Giannini EG, Marenco S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F: Hepatocellular carcinoma in patients without cirrhosis in Italy. Dig Liver Dis 2013, 45(2):164-169.
• [8]Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338.
• [9]CLIP investigator group: Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000, 31(4):840-845.
• [10]Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G: Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005, 54(3):411-418.
• [11]Alkofer B, Lepennec V, Chiche L: Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg 2011, 148(1):3-11.
• [12]Trevisani F, D’Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazziotti A, Grazi GL, Gozzetti G, Gasbarrini G, Bernardi M: Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995, 75(9):2220-2232.
• [13]Chang C, Chau G, Lui W, Tsay S, King K, Wu C: Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004, 139(3):320-5. discussion 326
• [14]Baffy G, Brunt EM, Caldwell SH: Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012, 56(6):1384-1391.
• [15]Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn W, Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011, 128(10):2436-2443.
• [16]Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA: Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol 2013, 5(9):186-194.
• [17]Caldwell SH, Crespo DM, Kang HS, Al-Osaimi , Abdullah MS: Obesity and hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S97-103.
• [18]Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Häggström C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H: Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012, 131(1):193-200.
• [19]Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348(17):1625-1638.
• [20]Rosmorduc O, Fartoux L: HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 2012, 36(3):202-208.
• [21]Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA: Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54(2):463-471.
• [22]Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle PR: IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009, 69(3):855-862.
• [23]Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ: JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009, 284(39):26591-26602.
• [24]Kuper H, Ye W, Broomé U, Romelsjö A, Mucci LA, Ekbom A, Adami HO, Trichopoulos D, Nyrén O: The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001, 34(4 Pt 1):714-718.
• [25]Chiang DJ, McCullough AJ: The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis 2014, 18(1):157-163.
• [26]Yuan J, Govindarajan S, Arakawa K, Yu MC: Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004, 101(5):1009-1017.
• [27]Sarpel U, Ayo D, Lobach I, Xu R, Newman E: Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford) 2012, 14(11):741-745.
• [28]Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL, Choti MA, Pawlik TM: Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014, 21(1):147-154.
• [29]Bège T, Le Treut YP, Hardwigsen J, Ananian P, Richa H, Campan P, Garcia S: Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series. J Gastrointest Surg 2007, 11(5):619-625.
• [30]Dupont-Bierre E, Compagnon P, Raoul J, Fayet G, de Lajarte-Thirouard A, Boudjema K: Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005, 201(5):663-670.
• [31]Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M, Broelsch CE: Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007, 205(1):27-36.
• [32]Laurent C, Blanc JF, Nobili S, Sa Cunha A, Le Bail B, Bioulac-Sage P, Balabaud C, Capdepont M, Saric J: Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 2005, 201(5):656-662.
• [33]Capussotti L, Muratore A, Amisano M, Massucco P, Polastri R, Bouzari H: Liver resection for large-size hepatocellular carcinomas in 47 non-cirrhotic patients–no mortality and long-term survival. Hepatogastroenterol 2006, 53(71):768-772.
• [34]Grazi GL, Cescon M, Ravaioli M, Ercolani G, Gardini A, Del Gaudio M, Vetrone G, Cavallari A: Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 2003, 17(Suppl 2):119-129.
• [35]Faber W, Sharafi S, Stockmann M, Denecke T, Sinn B, Puhl G, Bahra M, Malinowski MB, Neuhaus P, Seehofer D: Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery 2013, 153(4):510-517.